CY1122530T1 - Θεραπευτικος παραγων ή προφυλακτικος παραγων για ανοια - Google Patents
Θεραπευτικος παραγων ή προφυλακτικος παραγων για ανοιαInfo
- Publication number
- CY1122530T1 CY1122530T1 CY20191101311T CY191101311T CY1122530T1 CY 1122530 T1 CY1122530 T1 CY 1122530T1 CY 20191101311 T CY20191101311 T CY 20191101311T CY 191101311 T CY191101311 T CY 191101311T CY 1122530 T1 CY1122530 T1 CY 1122530T1
- Authority
- CY
- Cyprus
- Prior art keywords
- paragon
- dementia
- preventive
- therapy
- ser413
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
[ΣΚΟΠΟΣ] Η εφεύρεση παρέχει νέο θεραπευτικό παράγοντα ή προφυλακτικό παράγοντα για γνωστικές διαταραχές. [ΜΕΣΑ ΕΠΙΛΥΣΗΣ] Η εφεύρεση παρέχει αντίσωμα που συμμετέχει σε αντίδραση αντιγόνου-αντισώματος ειδικώς με ταυ πρωτεΐνη που έχει φωσφορυλιωθεί στη γειτονία της Ser413 της SEQ ID NO: 1 και θεραπευτικό παράγοντα ή προφυλακτικό παράγοντα για γνωστικές διαταραχές που περιλαμβάνει ως δραστικό συστατικό πεπτίδιο που έχει φωσφορυλιωθεί στη γειτονία του Ser413.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012124336 | 2012-05-31 | ||
| PCT/JP2013/065090 WO2013180238A1 (ja) | 2012-05-31 | 2013-05-30 | 認知症治療剤又は予防剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122530T1 true CY1122530T1 (el) | 2021-01-27 |
Family
ID=49673425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101311T CY1122530T1 (el) | 2012-05-31 | 2019-12-13 | Θεραπευτικος παραγων ή προφυλακτικος παραγων για ανοια |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20150183854A1 (el) |
| EP (2) | EP2857039B1 (el) |
| JP (3) | JP5971659B2 (el) |
| KR (2) | KR102208283B1 (el) |
| CN (1) | CN104602708B (el) |
| AR (1) | AR091218A1 (el) |
| AU (2) | AU2013268364B2 (el) |
| BR (1) | BR112014029566A2 (el) |
| CA (1) | CA2875205C (el) |
| CY (1) | CY1122530T1 (el) |
| DK (1) | DK2857039T3 (el) |
| ES (2) | ES2763361T3 (el) |
| HK (1) | HK1210031A1 (el) |
| HR (1) | HRP20192267T1 (el) |
| HU (1) | HUE046919T2 (el) |
| IL (1) | IL235899B (el) |
| LT (1) | LT2857039T (el) |
| ME (1) | ME03587B (el) |
| MX (1) | MX361128B (el) |
| MY (1) | MY172458A (el) |
| NZ (1) | NZ630536A (el) |
| PH (1) | PH12014502669B1 (el) |
| PL (1) | PL2857039T3 (el) |
| PT (1) | PT2857039T (el) |
| RS (1) | RS59802B1 (el) |
| RU (1) | RU2657438C2 (el) |
| SG (2) | SG11201407878VA (el) |
| SI (1) | SI2857039T1 (el) |
| TW (2) | TWI777183B (el) |
| WO (1) | WO2013180238A1 (el) |
| ZA (1) | ZA201409186B (el) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120244174A1 (en) | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| WO2012162179A1 (en) * | 2011-05-20 | 2012-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
| SI2857039T1 (sl) * | 2012-05-31 | 2020-03-31 | Osaka City University | Terapevtsko sredstvo ali profilaktično sredstvo za demenco |
| US9834596B2 (en) | 2012-07-03 | 2017-12-05 | Washington University | Antibodies to tau |
| TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗－ｔａｕ抗體 |
| US20190224339A1 (en) * | 2016-04-29 | 2019-07-25 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3519820B1 (en) * | 2016-09-30 | 2020-12-09 | H. Hoffnabb-La Roche Ag | Spr-based dual-binding assay for the functional analysis of multispecific molecules |
| MA47499A (fr) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc | Anticorps anti-tau et leurs procédés d'utilisation |
| JP2018139530A (ja) * | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| MX2019014174A (es) | 2017-05-30 | 2020-01-27 | Teijin Pharma Ltd | Anticuerpo anti-receptor de igf-i. |
| MA50629A (fr) | 2017-10-02 | 2021-03-31 | Merck Sharp & Dohme | Composés monobactames de chromane pour le traitement d'infections bactériennes |
| KR20200058480A (ko) | 2017-10-16 | 2020-05-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항-타우 항체 및 그의 용도 |
| EP3778631A4 (en) | 2018-04-06 | 2022-01-05 | Teijin Pharma Limited | Spns2 neutralizing antibody |
| EP3819378A4 (en) * | 2018-07-04 | 2022-09-14 | Aichi Medical University | OLIGONUCLEOTIDES FOR CONTROL OF TAU SPLICING AND THEIR USES |
| CN110028583B (zh) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
| JP7429404B2 (ja) * | 2019-08-06 | 2024-02-08 | 慶應義塾 | タウ関連疾患モデルの製造方法 |
| JPWO2021065306A1 (el) | 2019-09-30 | 2021-04-08 | ||
| WO2021189004A1 (en) * | 2020-03-19 | 2021-09-23 | Vascular Biosciences | Car peptide for improved coronavirus survival |
| IL299292A (en) * | 2020-06-25 | 2023-02-01 | Merck Sharp & Dohme Llc | High affinity antibodies targeting tau phosphorylated at serine 413 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (ja) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | ア−クヨウセツホウホウ |
| JP3587390B2 (ja) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法 |
| WO1997034145A1 (fr) * | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant |
| US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| EP2028932A4 (en) * | 2006-06-16 | 2011-10-12 | Vitruvean Llc | TAU AND AMYLOID FOREIGNER FRAGMENT EXPRESSING TRANSGENIC FLY |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| EP3329932A1 (en) * | 2009-06-10 | 2018-06-06 | New York University | Immunological targeting of pathological tau proteins |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| US20120244174A1 (en) * | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| TR201102696U (tr) * | 2011-05-27 | 2011-06-21 | Turhal Sal�H | Bağlantısız hareketli ürün reklam standı. |
| SI2857039T1 (sl) * | 2012-05-31 | 2020-03-31 | Osaka City University | Terapevtsko sredstvo ali profilaktično sredstvo za demenco |
-
2013
- 2013-05-30 SI SI201331636T patent/SI2857039T1/sl unknown
- 2013-05-30 MY MYPI2014703534A patent/MY172458A/en unknown
- 2013-05-30 KR KR1020207007010A patent/KR102208283B1/ko active Active
- 2013-05-30 WO PCT/JP2013/065090 patent/WO2013180238A1/ja active Application Filing
- 2013-05-30 ME MEP-2019-341A patent/ME03587B/me unknown
- 2013-05-30 PT PT137972907T patent/PT2857039T/pt unknown
- 2013-05-30 KR KR1020147035417A patent/KR102133610B1/ko active IP Right Grant
- 2013-05-30 EP EP13797290.7A patent/EP2857039B1/en active Active
- 2013-05-30 US US14/403,803 patent/US20150183854A1/en not_active Abandoned
- 2013-05-30 DK DK13797290.7T patent/DK2857039T3/da active
- 2013-05-30 JP JP2014518734A patent/JP5971659B2/ja active Active
- 2013-05-30 PL PL13797290T patent/PL2857039T3/pl unknown
- 2013-05-30 TW TW109121902A patent/TWI777183B/zh active
- 2013-05-30 AU AU2013268364A patent/AU2013268364B2/en active Active
- 2013-05-30 LT LTEP13797290.7T patent/LT2857039T/lt unknown
- 2013-05-30 AR ARP130101907 patent/AR091218A1/es active IP Right Grant
- 2013-05-30 RU RU2014153099A patent/RU2657438C2/ru active
- 2013-05-30 BR BR112014029566A patent/BR112014029566A2/pt not_active Application Discontinuation
- 2013-05-30 NZ NZ630536A patent/NZ630536A/en unknown
- 2013-05-30 SG SG11201407878VA patent/SG11201407878VA/en unknown
- 2013-05-30 ES ES13797290T patent/ES2763361T3/es active Active
- 2013-05-30 CN CN201380040658.9A patent/CN104602708B/zh active Active
- 2013-05-30 SG SG10201805410XA patent/SG10201805410XA/en unknown
- 2013-05-30 ES ES19207405T patent/ES2973070T3/es active Active
- 2013-05-30 EP EP19207405.2A patent/EP3662931B1/en active Active
- 2013-05-30 TW TW102119176A patent/TWI700296B/zh active
- 2013-05-30 MX MX2014014187A patent/MX361128B/es active IP Right Grant
- 2013-05-30 CA CA2875205A patent/CA2875205C/en active Active
- 2013-05-30 HU HUE13797290A patent/HUE046919T2/hu unknown
- 2013-05-30 RS RS20191640A patent/RS59802B1/sr unknown
-
2014
- 2014-11-25 IL IL235899A patent/IL235899B/en active IP Right Grant
- 2014-11-28 PH PH12014502669A patent/PH12014502669B1/en unknown
- 2014-12-12 ZA ZA2014/09186A patent/ZA201409186B/en unknown
-
2015
- 2015-11-03 HK HK15110820.8A patent/HK1210031A1/xx unknown
-
2016
- 2016-05-09 JP JP2016094112A patent/JP6406678B2/ja active Active
-
2018
- 2018-01-18 AU AU2018200413A patent/AU2018200413B2/en active Active
- 2018-03-19 JP JP2018051046A patent/JP6620829B2/ja active Active
-
2019
- 2019-06-10 US US16/436,301 patent/US20200148753A1/en not_active Abandoned
- 2019-12-13 CY CY20191101311T patent/CY1122530T1/el unknown
- 2019-12-17 HR HRP20192267TT patent/HRP20192267T1/hr unknown
-
2021
- 2021-12-01 US US17/539,926 patent/US20220340646A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122530T1 (el) | Θεραπευτικος παραγων ή προφυλακτικος παραγων για ανοια | |
| CY1123865T1 (el) | Τροποποιηση της εξειδικευσης δομημενου πολυπεπτιδιου | |
| CY1122826T1 (el) | Προ-συντηξης rsv f αντιγονα | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| CY1119766T1 (el) | Νεοι ρυθμιστες κινασης βενζοπυρανιου | |
| CY1122676T1 (el) | Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου | |
| CY1122458T1 (el) | Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων | |
| CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
| CY1122907T1 (el) | Διαγνωστικες αναλυσεις και kit για ανιχνευση υποδοχεα φολικου 1 | |
| PH12017501417A1 (en) | Anti-fap antibodies and methods of use | |
| CY1120246T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
| CY1123690T1 (el) | Ειδικα για cd40l ικριωματα που προερχονται απο τν3 και μεθοδοι χρησεως αυτων | |
| NZ730763A (en) | Methods of treating a tauopathy | |
| IN2014MN01642A (el) | ||
| EA201490029A1 (ru) | Соединения, ингибирующие металлоферменты | |
| BR112013020500A2 (pt) | anticorpo isolado, recombinante ou purificado | |
| MA39248B1 (fr) | Anticorps anti-jagged1 et procédés d'utilisation correspondants | |
| BR112013003248A2 (pt) | "macrociclo peptidomimético e seus usos" | |
| EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
| IN2014DN05885A (el) | ||
| NZ626242A (en) | Anti-asic1 antibodies and uses thereof | |
| CY1120132T1 (el) | Χρηση ρ3 πρωτεϊνων συντηξης βακτηριοφαγου ως παραγοντων δεσμευσης αμυλοειδους | |
| EP2552462A4 (en) | CCN3 THERAPEUTIC PEPTIDES AND THEIR ANALOGS | |
| MX353951B (es) | Anticuerpos de anti-teofilina y metodos de uso. | |
| MX2017014911A (es) | Fragmento fab de anticuerpo ngf anti-humano novedoso. |